risedronic acid has been researched along with prednisolone in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bax, DE; Chines, AA; Devogelaer, JP; Eastell, R; Nagant de Deuxchaisnes, C; Peel, NF; Russell, RG; Sacco-Gibson, N | 1 |
| Fujii, N; Hamano, T; Imai, E; Isaka, Y; Ito, T | 1 |
| Higashi, K; Hyodo, N; Hyodo, T; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Saigusa, T; Suzuki, S; Yamada, M; Yamamoto, K | 1 |
| Fujii, N; Hamano, T; Hori, M; Horio, M; Imai, E; Isaka, Y; Ito, T; Mikami, S; Moriyama, T; Nagasawa, Y | 1 |
| Ager, JW; Balooch, G; Balooch, M; Lane, NE; Nalla, RK; Porter, AE; Ritchie, RO; Yao, W | 1 |
| Ma, KM; Mok, CC; Siu, YP; To, CH; Tong, KH | 1 |
| Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K | 1 |
| Katayama, K; Matsuno, T | 1 |
| Busse, C; Cheng, Z; Lane, NE; Pham, A; Ritchie, RO; Yao, W; Zimmermann, EA | 1 |
| Bell, A; Brooklyn, TN; Creed, TJ; Fraser, WD; Kriel, MH; Linehan, J; Lockett, M; Probert, CS; Przemioslo, R; Smithson, JE; Tobias, JH | 1 |
| Hayashi, T; Hisahara, S; Hozuki, T; Imai, T; Matsumura, A; Shimohama, S; Suzuki, S; Toyoshima, T; Tsuda, E; Yamamoto, D; Yamauchi, R | 1 |
| Amemiya, N; Itabashi, M; Karasawa, K; Kawanishi, K; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Shimizu, A; Shiohira, S; Sugiura, H; Takei, T; Tsuchiya, K; Tsukada, M; Uchida, K | 1 |
| Fujita, Y; Maki, K; Uchikanbori, S; Watanabe, K | 1 |
| Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S | 1 |
| Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL | 1 |
| Soen, S | 1 |
| Arawaka, S; Fujiki, Y; Ishida, T; Kimura, Y; Kotani, T; Makino, S; Takeuchi, T; Yoshida, S | 1 |
| Akyuz, G; Ata, P; Delil, K; Gencer-Atalay, K; Ozgen, Z; Ozturk, EC; Yagci, I | 1 |
3 review(s) available for risedronic acid and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Mice; Middle Aged; Osteogenesis; Osteoporosis; Practice Guidelines as Topic; Prednisolone; Risedronic Acid; Risk; Teriparatide | 2014 |
Challenges in the treatment of fibrodysplasia ossificans progressiva.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density Conservation Agents; Breathing Exercises; Cushing Syndrome; Female; Humans; Indomethacin; Muscle Stretching Exercises; Myositis Ossificans; Physical Therapy Modalities; Prednisolone; Radiotherapy; Range of Motion, Articular; Risedronic Acid; Vitamin D; Young Adult; Zoledronic Acid | 2019 |
9 trial(s) available for risedronic acid and prednisolone
| Article | Year |
|---|---|
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis; Prednisolone; Risedronic Acid | 2000 |
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Etidronic Acid; Female; Glomerulonephritis; Humans; Male; Middle Aged; Prednisolone; Prospective Studies; Risedronic Acid | 2007 |
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Kidney Diseases; Male; Prednisolone; Prospective Studies; Risedronic Acid; Vitamin D | 2007 |
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents; Body Mass Index; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Prednisolone; Risedronic Acid; Treatment Outcome | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoclasts; Osteoporosis; Osteoprotegerin; Peptides; Prednisolone; Prospective Studies; RANK Ligand; Risedronic Acid; Vitamin K 2 | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Family Practice; Female; Fractures, Bone; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Pruritus; Retrospective Studies; Risedronic Acid; Time Factors | 2008 |
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Hip Joint; Humans; Inflammatory Bowel Diseases; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prednisolone; Risedronic Acid | 2010 |
Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neuromuscular Diseases; Osteocalcin; Peptides; Pilot Projects; Prednisolone; Risedronic Acid; Treatment Outcome; Vitamin K 2 | 2010 |
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Male; Middle Aged; Nephrosis, Lipoid; Osteoporosis; Prednisolone; Prospective Studies; Risedronic Acid; Risk Factors; Young Adult | 2010 |
10 other study(ies) available for risedronic acid and prednisolone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
[Risedronate: a possible treatment for extraosseous calcification].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; CREST Syndrome; Etidronic Acid; Female; Glucocorticoids; Humans; Joint Diseases; Middle Aged; Ossification, Heterotopic; Osteoporosis; Prednisolone; Risedronic Acid; Shoulder Joint | 2005 |
The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids.
Topics: Animals; Biomechanical Phenomena; Biopsy; Bone Density Conservation Agents; Calcification, Physiologic; Drug Interactions; Elasticity; Etidronic Acid; Glucocorticoids; Humans; Ilium; Lumbar Vertebrae; Male; Mice; Microscopy, Electron, Transmission; Prednisolone; Risedronic Acid; Tomography, X-Ray | 2007 |
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
Topics: Animals; Calcification, Physiologic; Etidronic Acid; Gene Expression; Glucocorticoids; Immunohistochemistry; Male; Mice; Osteocalcin; Osteogenesis; Parathyroid Hormone; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; Risedronic Acid; Tomography, X-Ray Computed; Wnt Proteins | 2008 |
Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.
Topics: Anatomy, Cross-Sectional; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Male; Mandible; Minerals; Organ Size; Osteoblasts; Osteogenesis; Osteoporosis; Periosteum; Prednisolone; Rats; Rats, Wistar; Risedronic Acid; Time Factors; Tomography, X-Ray Computed | 2011 |
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Middle Aged; Osteomalacia; Prednisolone; Risedronic Acid; Sjogren's Syndrome; Sodium Bicarbonate; Treatment Outcome | 2013 |
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Glucocorticoids; Male; Osteoporosis; Plant Extracts; Prednisolone; Rats; Risedronic Acid; Tibia; Triticum | 2014 |
Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Female; Glucocorticoids; Humans; Lumbar Vertebrae; Lupus Erythematosus, Systemic; Male; Middle Aged; Osteoporosis; Pelvic Bones; Prednisolone; Protective Factors; Risedronic Acid; Risk Factors; Tartrate-Resistant Acid Phosphatase; Time Factors; Treatment Outcome | 2018 |